期刊文献+

补肾活血方对强直性脊柱炎患者RANKL/OPG表达的影响 被引量:15

Effect of Bushen Huoxue Decoction on Receptor Activator of Nuclear Factor-kappa B Ligand and Osteoprotegerin in Patients with Ankylosing Spondylitis
原文传递
导出
摘要 目的:观察补肾活血方对强直性脊柱炎(AS)患者细胞核因子-κB受体活化因子配体(RANKL)、护骨素(OPG)的影响。方法:将65例AS患者随机分为2组:西医组(32例)采用柳氮磺胺吡啶治疗;中西医结合组(33例)采用补肾活血方联合柳氮磺胺吡啶治疗,均治疗3月。运用ELISA法测血清RANKL、OPG、骨钙素(OC)、Ⅰ型胶原C端肽(CTX)的表达水平。结果:2组治疗后血清RANKL含量均较治疗前明显下降(P<0.05,P<0.01),OPG含量均较治疗前明显升高(P<0.05),RANKL/OPG比值显著下降(P<0.05,P<0.01)。治疗后2组RANKL、RANKL/OPG比值比较,差异也有显著性意义(P<0.05)。治疗后2组血清OC水平均较治疗前显著升高(P<0.05,P<0.01),CTX水平均较治疗前显著降低(P<0.05,P<0.01),且中西医结合组OC水平变化更为显著(P<0.05)。结论:补肾活血方影响R ANKL/R ANK/OPG系统可能是其阻止AS骨质破坏的作用机理之一。 Objective: To observe the effect of Bushen Huoxue Decoction on receptor activator of nuclear factors-kappa B ligand (RANKL)and osteoprotegerin(OPG) in patients with ankylosing spondylitis (AS). Methods:Sixty-five patients with AS were randomized into two groups. Western medicine group (n=32) was treated with sulfasalazine (SSZ) for three months. Combination group (n=33) was treated with Bushen Huoxue Decoction combined with SSZ for three months too. Serum levels of RANKL, OPG, osteocalcin(OC) and C-terminal cross-linking telopeptide of type I collagen (CTX)were detected by ELISA. Results: Serum RANKL levels was decreased obviously in both groups after treatment(P 〈 0.05, P 〈 0.01compared with that before treatment).Serum OPG level was elevated significantly in both groups after treatment(P 〈 0.05). RANKL/OPG ratio was decreased obviously in both groups after treatment (P 〈 0.05, P 〈 0.01 compared with that before treatment). There was significant difference between the two groups after treatment(P 〈 0.05).Serum OC level was elevated obviously and serum CTX level was decreased obviously after treatment (P 〈 0.05, P 〈 0.01 compared with those before treatment). There was significant difference between the two groups after treatment in serum OC level (P 〈 0.05). Conclusion. Bushen Huoxue Decoction has an effect on regulating RANKL/RANKL/OPG system, which may be one of its mechanisms in preventing bone destruction in AS patients.
出处 《新中医》 CAS 2012年第1期55-57,共3页 New Chinese Medicine
关键词 强直性脊柱炎 中医疗法 补肾活血方 Ankylosing Spondylitis TCM Therapy Bushen Huoxue Decoction
  • 相关文献

参考文献7

  • 1王玉,徐胜前.RANKL/RANK/OPG系统与强直性脊柱炎相关性研究进展[J].医学研究杂志,2010,39(6):117-120. 被引量:3
  • 2Vander Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria [J]. Arthritis Rheum, 1984, 27(4): 361-368.
  • 3中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:54-58.
  • 4中华中医药学会.中医内科常见病诊疗指南:西医疾病部分[M].北京:中国中医药出版社,2008:55-56.
  • 5Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity lndex[J]. J Rheumator, 1994, 21(12).. 2286- 2291.
  • 6罗成燕,王凌,李大金.RANKL-RANK-OPG环路在骨免疫网络中的调节作用[J].中国免疫学杂志,2008,24(4):381-384. 被引量:9
  • 7Kim HR, Kim HY, Lee SH. Elevated serum levels of soluble receptor activator of nuclear factors-kappa B ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS)[J]. Rheumatorogy (Oxford), 2006, 45(10): 1197-1200.

二级参考文献55

  • 1赵伟,黄烽.护骨素在强直性脊柱炎外周关节骨质破坏病理机制中的作用[J].中华风湿病学杂志,2005,9(6):329-333. 被引量:17
  • 2Lorenzo J,Horowitz M,Choi Y.Osteoimmunology:interactions of the bone and immune system.Endocr Rev,2008,29(4):403-440.
  • 3Wada T,Nakashima T,Hiroshi N,et al.RANKL-RANK signaling in osteoclastogenesis and bone disease.Trends Mol Med,2006,12(1):17-25.
  • 4Hikita A,Yana I,Wakeyama H,et al.Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand.J Biol Chem,2006,281(48):36846-36855.
  • 5Leibbrandt A,Penninger JM.RANK/RANKL:regulators of immune responses and bone physiology.Ann N Y Acad Sci,2008,143(1):123-150.
  • 6Miller PD.Denosumab:anti-RANKL antibody.Curr Osteoporos Rep,2009,7(1):18-22.
  • 7Lloyd SA,Yuan YY,Kostenuik PJ,et al.Soluble RANKL induces high bone turnover and decreases bone volume,density,and strength in mice.Calcif Tissue Int.2008,82(5):361-372.
  • 8Bekker PJ,Holloway D,Nakanishi A,et al.The effect of a single dose of osteoprotegerin in postmenopausal women.J Bone Miner Res,2001,16(2):348-360.
  • 9Miranda-Carús ME,Benito-Miguel M,Balsa A,et al.Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promoteoste oclastogenesis in autologous monocytes.Arthritis Rheum,2006,54(4):1151-1164.
  • 10Kearns AE,Khosla S,Kostenuik PJ.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.Endocr Rev,2008,29(2):155-192.

共引文献1278

同被引文献190

引证文献15

二级引证文献157

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部